CABA · Cabaletta Bio, Inc.
$3.19
+0.09 (+2.90%)
At close · Aug 20
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We have identified conditions that raise substantial doubt about our ability to continue as a going concern. If we are unable to secure additional funding beyond our current cash position that enables our operations into mid-2027, we may be forced to delay, reduce or discontinue our product development programs efforts or other operations. Accordingly, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$540.85M
Shares
169.55M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Scott Brun, M.D. | Chair of the NCG Committee | Appointed | 2023-07-24 |
| Mark Simon | Chair of the NCG Committee | Resigned | 2023-07-24 |
| Mark Simon | Chair of the Compensation Committee | Appointed | 2023-07-24 |
| Catherine Bollard, M.D. | Chair of the Compensation Committee | Resigned | 2023-07-24 |
| Shawn Tomasello | Board of Directors | Appointed | 2023-07-24 |
| Scott Brun, M.D. | Class I director | Appointed | 2023-06-01 |
| Scott C. Brun, M.D. | Class I director | Appointed | 2021-06-28 |
| Brian Daniels, M.D. | member of the Board and all committees of the Board | Resigned | 2021-06-28 |
Key facts
CIK
1759138
CUSIP
12674W109
13F (30d)
148 filings
142 filers
Visit website
Investor relations